Treatment with lepirudin in heparin induced thrombocytopenia;Traitement par lépirudine au cours d'une thrombopénie à l'héparine: À propos d'un cas

Archives des Maladies du Coeur et des Vaisseaux

Volumn 95, Issue 12, 2002, Pages 1234-1238

  Nippert, M ^a   De Maistre, E ^a   Rodermann, M ^a   Vancon A C ^a   Amrein, D ^a   Brembilla Perrot, B ^a   Lecompte, T ^a   Zannad, F ^a   Aliot, E ^a  

^a Département des Maladies Cardiovasculaires

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; DRUG INDUCED DISEASE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LUNG EMBOLISM; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0036947859     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Nguyen P, de Maistre E, Cornillet-Lefebvre P, Regnault V, Lecompte T. Heparin-induced thrambocytopenia in France 1980-1998. Semin Thromb Haemost 1999; 25 (Suppl. 1): 9-15.
2. Warkentin TE, Levine MN, Hirsh J et al. Heporin-induced thrombocytopenio in patients treated with low-molecular-weight heporin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
3. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-51.
4. Greinacher A, Lubenaw N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103: 1479-84.
5. Poetzsch B, Hund S, Madlener K, Unkrig C, Mueller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based clotting assay. Thromb Res 1997; 86: 373-83.
6. Schiele F, Lindgaerde F, Eriksson H et al., for the International Multicentre Hirudin Study Group. Subcutaneous recambinant hirudin (HBW 023) versus intravenous sadium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. Thromb Haemost 1997; 77: 834-8.
7. Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
8. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
9. Olbrich K, Wiersbitzky M, Wacke W et al. A typical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with -ultra-low-dose rt-PA lysis and recombinant hirudin (lepirudin). Blood Coag Fibrinol 1998; 9: 273-7.
10. Pineau E, Le Bret E, Folliguet T, Saint Maurice O, Carbognani D, Laborde F. Utilisatian de l'Orgaran, hérarinoï de synthèse, lors cle deux circulatians extracorporelles, chez un même patient allergique à l'héparine. Arch Mal Cœur 2001; 94: 1447-57.
11. Longrois D, de Maistre E, Bischoff N et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anesth 2000; 47: 255-60.
12. Schiele F, Vuillemenot A, Kramarz P et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-62.
13. Parent F, Bridey F, Dreyfus M et al. Treatment af severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70: 386-8.
14. Simmonneau G, Azarian R, Brenot F, Dartevelle PG, Musset D, Duroux P. Surgical management of unresolved pulmonary embolism. Chest 1995; 107: 52S-55S.